Inactive Instrument

Analyst Reco. Novartis AG Xetra

Equities

NOVARTIS AG : Barclays reaffirms its Sell rating	06-24	ZD
NOVARTIS AG : JP Morgan reiterates its Neutral rating	06-11	ZD
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation	06-06	MT
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists	06-06	RE
NOVARTIS AG : Deutsche Bank maintains a Buy rating	06-05	ZD
Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation	06-04	MT
NOVARTIS AG : JP Morgan remains Neutral	06-03	ZD
NOVARTIS AG : Buy rating from Goldman Sachs	06-03	ZD
NOVARTIS : UBS reiterates buy recommendation after ASCO	06-03	CF
NOVARTIS AG : UBS gives a Buy rating	06-03	ZD
NOVARTIS AG : UBS reiterates its Buy rating	05-31	ZD
NOVARTIS AG : Jefferies remains its Buy rating	05-31	ZD
Goldman Sachs Starts Novartis With Buy Rating, $120 Price Target	05-30	MT
NOVARTIS AG : From Sell to buy Rating by Goldman Sachs	05-30	ZD
NOVARTIS AG : Deutsche Bank remains its Buy rating	05-24	ZD
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating	05-23	MT
NOVARTIS AG : Berenberg remains Neutral	05-23	ZD
NOVARTIS AG : UBS maintains a Buy rating	05-06	ZD
NOVARTIS AG : Receives a Buy rating from Jefferies	04-26	ZD
BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	04-24	MT